Project Grant R01HL181134
Award Date 8/25/25
Completion Date 5/31/29
Dollars Obligated $772K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This $700,338 federal Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of Texas Southwestern Medical Center to study the molecular mechanisms by which the protein complex "retriever" regulates cholesterol homeostasis and LDL receptor recycling. The research aims to obtain a detailed structural and functional understanding of how retriever interacts with other critical protein...
- This federal Project Grant award, totaling $135,930, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant supports research on the role of the TRPM7 ion channel in macrophage signaling and its impact on atherosclerosis, a leading cause of cardiovascular disease. The key objectives of the research are to: 1) generate macrophage-specific TRPM7 deletion mice and subject them to a high-fat, Western diet...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
- This $548,816 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of Illinois focused on understanding the role of the SEC16B protein in regulating lipid metabolism and the formation of lipid droplets in the liver. The goal is to elucidate the function and mechanisms by which SEC16B modulates very low-density lipoprotein (VLDL) secretion and lipid droplet dynamics, which are key processes in...
- The University of Maryland, Baltimore was awarded a $752,709 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on August 18, 2025. The grant supports research to investigate the cell type-specific roles of the integrin CD11b in atherosclerosis regression. Atherosclerosis is a major cardiovascular disease with significant healthcare costs in the U.S., and this research aims to develop new therapies that can more effectively promote...
- The Department of Health and Human Services, National Heart, Lung, and Blood Institute (NHLBI) awarded a $787,453 Project Grant to Brigham & Women's Hospital Inc. under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports the development of a new lipid-lowering and anti-inflammatory siRNA therapy for more effective treatment of atherosclerotic cardiovascular disease (ASCVD). The research aims to target the epsin endocytic adaptor proteins in both the liver and...
- This federal Project Grant award of $618,450.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research focused on identifying key regulators of vascular homeostasis and understanding how they maintain normal vascular function. The principal investigator will use a combination of in silico and in vitro screening approaches to identify the RNA-binding protein PABPC1 as a critical suppressor of endothelial cell activation, which can...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $705,405.00 in funding to The Leland Stanford Junior University (Stanford University) to conduct research on "Adventitial Fibroblast Phenotypic Modulation in Atherosclerosis". The project aims to characterize a novel population of adventitial fibroblast cells that play a pathogenic role in atherosclerosis, with the goal of identifying new...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,364,153 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New York University's NYU Long Island School of Medicine to conduct research on reducing plasma cholesterol and atherosclerosis using a microRNA-30c analog called C2. The project aims to identify novel ways to reduce plasma cholesterol levels and the risk of developing cardiovascular disease. The key objectives are to investigate the molecular mechanisms by...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $128,341 to Baylor College of Medicine to investigate the role of endothelial cell nucleotide synthesis in the development of atherosclerosis. The project aims to understand how disturbed blood flow induces endothelial cell DNA damage and death, compromising the endothelial barrier and leading to atherosclerotic lesion formation. The research will focus on the...